Scientific Programme
Wednesday, 7 December 2022
8:30-9:30
UCARE business meeting
8:30-10:00
Registration
10:00-10:15
Welcome, introduction and objectives
Ana Giménez-Arnau (Spain)
Torsten Zuberbier (Germany)
Marcus Maurer (Germany)
10:15-10:45
Recurrent mast cell mediated angioedema without wheals – what are we missing?
Marta Ferrer (Spain) & Markus Magerl (Germany)
Oral Presentation Session I: The aetiopathogenesis of urticaria
10:45-11:05
Causes of chronic urticaria – Open questions
and how to answer them
Allen Kaplan (USA) & Riccardo Asero (Italy)
11:05-11:14
OP.001 Mast cell-derived GM-CSF and physical interaction in the skin promotes bidirectional mast cell-eosinophil activation
Stefan Frischbutter (Germany)
11:14-11:23
OP.002 Transcriptome analysis of experimentally-induced wheals in patients with cold urticaria
Nasser Mohammad-Porras (Spain)
11:23-11:32
OP.003 The significant changes in the gene expression of STAT3, IL-27, and IL-35 in patients with chronic spontaneous urticaria
Maryam Khoshkhui (Iran)
11:32-11:41
OP.004 The role of skin chemokines in the pathogenesis of CSU
Elias Toubi (Israel)
11:41-11:50
OP.005 Investigating endothelial dysfunction in chronic spontaneous urticaria
Katie Ridge (Ireland)
11:50-12:15
sponsored Coffee Break
EMBRN Session:
The biology of mast cells and basophils and their role in health and disease
12:15-12:20
Introduction
Francesca Levi-Schaffer (Israel)
12:20-12:45
12:45-13:10
Development of an anti-IgE vaccine for the treatment of IgE- and mast cell/basophil-mediated diseases
Laurent Reber (France)
Autoreactive IgE and basophils in autoimmunity
Nicolas Charles (France)
13:10-13:15
Discussion and Q&A
Francesca Levi-Schaffer (Israel)
13:15-14:20
Lunch Break
Oral Presentation Session II: Differential diagnosis, comorbidities, diagnostic approaches and biomarkers
14:20-14:40
The diagnostic workup of chronic urticaria – Dos and Don’ts
Karla Arruda (Brazil) & Constance Katelaris (Australia)
14:40-14:49
OP.006 Cold urticaria and anaphylaxis are associated with hereditary α-tryptasemia and KIT p.D816V
Mojca Bizjak (Slowenia)
14:49-14:58
OP.007 PREDICT-CU: Predicting time to clinical remission in chronic urticaria
Maria-Magdalena Balp (Switzerland)
14:58-15:07
OP.008 Remibrutinib inhibits mastcell and basophil activation in chronic urticaria independently of FcεR1 expression
Ana Giménez-Arnau (Spain)
14:07-15:16
OP.009 Urticaria in patients with suspected mast cell activation syndrome
Fabiana Nunes Oliveira (Brazil)
14:16-15:25
OP.010 In chronic spontaneous urticaria, fever, pain and malaise are common and linked to active and uncontrolled disease: Results from the Chronic Urticaria Registry (CURE)
Polina Pyatilova (Germany)
15:25-15:55
Assessing CU patients for biomarkers and disease
status – How to harmonize our approach
Ana Giménez-Arnau (Spain) & Pavel Kolkhir (Germany)
15:55-16:20
sponsored Coffee Break
Workshop
16:20-16:27
Introduction and overview over past UCARE Projects
Ana Giménez-Arnau (Spain) & Marcus Maurer (Germany)
16:27-17:03
Quick Presentations of current and upcoming UCARE Projects
Project Leaders
17:03-17:13
Presentation of CURE and CRUSE Control
Yana Hackler, Karsten Weller & Sophia Neisinger (Germany)
17:13-17:20
Discussion, Questions and Wrap-up
Ana Giménez-Arnau (Spain) & Marcus Maurer (Germany)
Oral Presentation Session III: Urticaria treatments and predictors of response
17:20-17:40
Findings from recent and ongoing urticaria studies and trials
Torsten Zuberbier (Germany) & Emek Kocatürk (Turkey)
17:40-17:49
OP.011 Remibrutinib for Chronic Spontaneous Urticaria: Time to Complete Urticaria Control
Petra Staubach-Renz (Germany)
17:49-17:58
OP.012 Long-term safety of remibrutinib in CSU patients: Phase 2b study
Ana Giménez-Arnau (Spain)
17:58-18:07
OP.013 Dupilumab Efficacy in Patients with Chronic Spontaneous Urticaria with Comorbidities
Marcus Maurer (Germany)
18:07-18:16
OP.014 Cold urticaria patients achieve complete response with 1.5 mg/kg barzolvolimab
Dorothea Terhorst-Molawi (USA)
18:16-18:25
OP.015 Elevated levels of soluble FcεRI as a biomarker of early and good response to omalizumab treatment in chronic spontaneous urticaria
Sherezade Moñino-Romero (Germany)
18:25-18:34
OP.016 Differences between pediatric and adult urticaria: patient characteristics, treatment response and indicators of response
Sinem Ornek Ozdemir (Turkey)
18:34-18:43
OP.017 Autoimmunity and low IgE in CSU: a prospective analysis
David Pesqué (Spain)
18:43-18:52
OP.018 Anti-TPO/total IgE ratio – biomarker for omalizumab response prediction in CSU
Rita Brás (Portugal)
18:52-19:00
Closing remarks
Ana Giménez-Arnau (Spain)
Torsten Zuberbier (Germany)
Marcus Maurer (Germany)
19:00
Scientific Dinner Reception
Langenbeck-Virchow-Haus
Thursday, 8 December 2022
07:15-08:30
Registration
08:30-08:45
Welcome
Ana Giménez-Arnau (Spain)
Torsten Zuberbier (Germany)
Marcus Maurer (Germany)
Oral Presentation Session IV: Treatment of urticaria
08:45-09:05
Current and novel treatment targets and approaches
Martin Metz (Germany) & Sarbjit Saini (USA)
09:05-09:14
OP.019 Multi-dosed barzolvolimab is effective in chronic spontaneous urticaria
Marcus Maurer (Germany)
09:14-09:23
OP.020 Treatment with MRGPRX2 Antagonist EP262 Potently Inhibits Mast Cell Degranulation
Veena Viswanath (USA)
09:23-09:32
OP.021 Remibrutinib improves CSU in patients with low or high IgE
Michihiro Hide (Japan)
09:32-09:41
OP.022 Anti-IL-23 treatment in patients with omalizumab-refractory chronic spontaneous urticaria – a case series
Hanna Bonnekoh (Germany)
09:41-09:50
OP.023 Omalizumab drug survival for chronic urticaria – the DruSO-CU UCARE study
Reineke Soegiharto (The Netherlands)
09:50-09:59
OP.024 CRUSE – What the first 100 days have taught us
Sophia Neisinger (Germany)
10:00-11:10
Poster Session
11:10-11:50
Coffee Break
Interactive Case Journey
11:50-13:00
Problems you like, solutions you’re looking for –
An interactive patient journey
Facilitators: Karoline Krause (Germany) & Frank Siebenhaar (Germany)
13:00-14:30
sponsored Lunch Break
ACARE Session: Recurrent angioedema
14:30-14:35
Introduction
Markus Magerl (Germany)
14:35-14:48
Erythema marginatum as initial phase of an hereditary angioedema attack
Kinga Viktoria Kohalmi (Hungary)
14:48-15:01
Importance of the complement test in patients with angioedema taking ACE inhibitor
Henriette Farkas (Hungary)
15:01-15:14
The use of anti-IgE therapy to define idiopathic non-histaminergic angioedema
Jason Fok (Australia)
15:14-15:27
Estrogen triggering non-hereditary Angioedema
Anete Grumach (Brazil)
15:27-15:40
ACARE projects and activities
Markus Magerl (Germany)
Closing Session
15:40-16:10
The future of urticariology – What are the unmet needs we need to address and how will we do this
Marcus Maurer (Germany) & Jonathan Bernstein (USA)
16:10-16:20
Closing remarks
Ana Giménez-Arnau (Spain)
Torsten Zuberbier (Germany)
Marcus Maurer (Germany)
Industry Session
Thursday, 8 Decemeber 2022
07:30-08:15
Sponsored Breakfast Symposium
Type 2 Inflammation in CSU: Emerging Evidence and Implications
